JPMorgan Chase & Co. Acquires 277,827 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

JPMorgan Chase & Co. grew its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 138.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 477,800 shares of the company's stock after acquiring an additional 277,827 shares during the quarter. JPMorgan Chase & Co. owned 0.66% of Kiniksa Pharmaceuticals worth $9,451,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in KNSA. Raymond James Financial Inc. bought a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth $3,955,000. Globeflex Capital L P raised its stake in shares of Kiniksa Pharmaceuticals by 217.1% during the 4th quarter. Globeflex Capital L P now owns 88,596 shares of the company's stock worth $1,752,000 after purchasing an additional 60,656 shares during the period. Wellington Management Group LLP purchased a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter worth about $1,192,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Kiniksa Pharmaceuticals during the third quarter valued at about $1,105,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Kiniksa Pharmaceuticals by 36.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company's stock worth $2,414,000 after buying an additional 32,393 shares during the last quarter. Institutional investors own 53.95% of the company's stock.

Insider Buying and Selling

In related news, CFO Mark Ragosa sold 36,372 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total transaction of $809,277.00. Following the completion of the transaction, the chief financial officer now directly owns 22,958 shares in the company, valued at $510,815.50. The trade was a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Eben Tessari sold 12,000 shares of the firm's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $20.48, for a total value of $245,760.00. Following the completion of the sale, the chief operating officer now directly owns 77,363 shares in the company, valued at approximately $1,584,394.24. The trade was a 13.43 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 91,766 shares of company stock valued at $2,002,135. Company insiders own 54.57% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Wedbush restated an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $37.17.

Kiniksa Pharmaceuticals Stock Performance

KNSA stock traded down $0.32 during midday trading on Friday, reaching $20.21. 529,238 shares of the company's stock traded hands, compared to its average volume of 462,731. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15. The company has a 50-day moving average price of $21.04 and a two-hundred day moving average price of $21.53. The firm has a market capitalization of $1.47 billion, a PE ratio of -144.35 and a beta of 0.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. During the same quarter in the prior year, the business earned $0.35 EPS. The firm's revenue for the quarter was up 46.9% compared to the same quarter last year. As a group, analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.